Vident Advisory’s Sage Therapeutics SAGE Stock Holding History

Vident Advisory’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,528	Closed	-$179K	–	1532
2024 Q2	$179K	Buy	+16,528	New	+$212K	0.01%	1311

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vident Advisory's SAGE Position: Q3 2024 in Review

Vident Advisory sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 16,528 shares — an estimated $179K sold.

Vident Advisory first reported a position in SAGE in Q2 2024 and held it in 1 quarter. The position peaked at $179K in Q2 2024. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

Vident Advisory reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
Vident Advisory sold 16,528 Sage Therapeutics shares in Q3 2024, an estimated $179K.
Vident Advisory first reported a position in Sage Therapeutics in Q2 2024 and held it in 1 quarter.
Vident Advisory's Sage Therapeutics position peaked at $179K in Q2 2024.
176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.